PwPepwise

Gonadorelin

Sex & Libido

a.k.a. Factrel

Synthetic GnRH

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), a naturally occurring signaling molecule produced in the hypothalamus.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Human — Pediatric cryptorchidism (neoadjuvant/perioperative)1.2 mgDailyIntranasalSprayed into the nose.6 mos
Human — Diagnostic GnRH stimulation testing (LH/FSH provocative test)100 mcgDailyIntravenousInjected directly into a vein.—
Bovine reproductive synchronization (Ovsynch/CO-Synch/Double-Ovsynch protocols)100 mcgDailyIntramuscularInjected into a muscle.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), a naturally occurring signaling molecule produced in the hypothalamus that instructs the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones in turn regulate testosterone, estrogen, and overall reproductive function in both males and females. Because it mimics the body's own hormonal trigger, gonadorelin is used in a variety of clinical contexts involving reproductive health and hormonal assessment.

In pediatric medicine, gonadorelin administered as a nasal spray has been studied to support testicular development in boys with undescended testes, where perioperative treatment may improve long-term testicular volume outcomes1. As a diagnostic tool, gonadorelin stimulates measurable LH and FSH responses that help clinicians evaluate pituitary function and diagnose conditions such as central precocious puberty (CPP) in girls, with evidence suggesting that BMI may influence the magnitude of that response16,17. In veterinary reproductive medicine, gonadorelin is extensively used to synchronize ovulation in cattle as part of timed artificial insemination protocols, where it reliably induces ovulatory responses and supports pregnancy outcomes3,5,8. Human safety data from clinical studies appears reassuring in the short to medium term11, and the compound's long track record in both human and veterinary medicine supports a well-characterized tolerability profile across multiple populations and routes of administration.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Gonadorelin is a synthetic decapeptide structurally identical to endogenous hypothalamic gonadotropin-releasing hormone (GnRH-I), with the amino acid sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. It acts as a full agonist at pituitary GnRH receptors (GnRH-R), which are seven-transmembrane G-protein-coupled receptors coupled primarily to Gαq/11. Upon receptor binding, gonadorelin activates phospholipase C, generating inositol trisphosphate (IP₃) and diacylglycerol (DAG), which mobilize intracellular calcium and activate protein kinase C. This signaling cascade drives the synthesis and pulsatile release of both LH and FSH from pituitary gonadotroph cells into the systemic circulation17.

The downstream effects of LH and FSH are gonad-specific. In females, LH triggers the preovulatory LH surge that induces follicular rupture and ovulation, promotes corpus luteum formation, and stimulates progesterone synthesis; FSH drives follicular recruitment and estrogen biosynthesis. In males, LH stimulates Leydig cell testosterone production, while FSH supports Sertoli cell function and spermatogenesis. The gonadorelin-stimulated LH response is the basis of standard GnRH provocative testing for central precocious puberty16,20 and for evaluating hypothalamic-pituitary-gonadal axis integrity17.

In cattle, intramuscular gonadorelin induces a measurable LH surge within 30–60 minutes of administration, producing follicular luteinization or ovulation depending on the follicular stage at treatment. The magnitude of the ovulatory response is modulated by preexisting circulating progesterone and dominant follicle size at the time of injection — cows with elevated progesterone and appropriately sized dominant follicles show the highest ovulatory response to GnRH3,10,14. Repeated GnRH administration on day 5 post-ovulation can induce accessory corpus luteum formation, significantly increasing circulating progesterone and potentially supporting embryo survival in stage-dependent contexts4.

Gonadorelin has a short plasma half-life of approximately 2–10 minutes following intravenous administration, due to rapid enzymatic cleavage by endopeptidases and aminopeptidases in the blood and hypothalamus. This short duration of action is pharmacologically important: continuous or sustained-release GnRH agonist exposure causes pituitary GnRH receptor downregulation and desensitization, paradoxically suppressing LH and FSH — the basis of long-acting GnRH agonist therapy in hormone-sensitive conditions. Pulsatile or bolus administration, as used clinically with gonadorelin, preserves receptor sensitivity and maintains stimulatory gonadotropin output. Intranasal delivery achieves lower and more variable systemic bioavailability than intravenous routes but has been employed effectively in pediatric protocols1,11.

§04Evidence & efficacy

Evidence base
372Studies
152Human
92Animal

Gonadorelin demonstrates well-characterized efficacy as a diagnostic agent and as a component of ovulation synchronization protocols, with emerging evidence across additional reproductive indications.

Diagnostic use (central precocious puberty): Gonadorelin reliably stimulates LH and FSH secretion when administered intravenously, supporting its established role in pituitary function testing17. In girls being evaluated for central precocious puberty, gonadorelin-stimulated LH peak achieves excellent diagnostic accuracy with a reported cut-off of approximately 4.7 IU/L (sensitivity 100%, specificity 87%, AUC 0.982)20. BMI significantly attenuates the LH response to gonadorelin stimulation — obese girls demonstrate meaningfully lower peak LH than normal-weight peers — suggesting that BMI-stratified diagnostic thresholds may improve diagnostic accuracy16.

Pediatric cryptorchidism: Perioperative intranasal gonadorelin (1.2 mg/day for 8 weeks) appears to improve long-term testicular volume outcomes as measured by testicular atrophy index at 5-year follow-up in unilateral cryptorchidism1. Boys with a baseline testicular atrophy index above 20% may show the most pronounced benefit1. A separate safety-focused study found no significant difference from controls on hormonal surrogate endpoints at the time of orchidopexy, with fertility-related histological outcomes under ongoing investigation11.

Bovine ovulation synchronization: In cattle, gonadorelin at 100–200 mcg is a reliable inducer of LH release and ovulatory response when incorporated into Ovsynch, CO-Synch, and Double-Ovsynch protocols3,5,8,14,15. Higher doses (200 mcg) increase ovulatory response to the first GnRH injection, particularly in cows with elevated baseline progesterone3,19, and may improve pregnancy per AI at first service in lactating dairy cows19. However, dose escalation does not consistently translate into improved pregnancy rates across all protocol contexts7,10, and GnRH administered at the time of estrus-detected AI does not improve pregnancy outcomes over controls12. Post-ovulatory GnRH on day 5 may reduce pregnancy loss in recipients of expanded blastocyst-stage embryos specifically4. Presynchronization strategies that improve ovulatory response to the first GnRH injection tend to enhance downstream synchronization quality8.

§05Safety

Gonadorelin has been studied in both human and veterinary contexts, with an overall tolerability profile that appears favorable across the evidence base.

In pediatric human studies, intranasal gonadorelin administered perioperatively in infants with undescended testes showed no significant adverse effects on penile development, testicular volume, or hormonal profiles (LH, FSH, testosterone, Inhibin B, AMH) at the time of orchidopexy11. No safety or adverse event data were reported in the perioperative RCT assessing long-term testicular volume outcomes1, which is an area where further characterization is ongoing.

In adult female volunteers, intravenous gonadorelin at 100 mcg was well tolerated, with no specific adverse events reported17. Acute alcohol co-administration at intoxicating blood levels did not produce adverse interactions with gonadorelin-stimulated gonadotropin release17.

In bovine veterinary use across multiple large RCTs involving thousands of animals, gonadorelin administered intramuscularly at doses of 86–200 mcg was consistently well tolerated, with no adverse events reported across studies2,3,4,5,6,7,8,9,10,12,13,14,15. Milk production in treated dairy cows was not significantly affected by gonadorelin administration13.

Long-term human safety data, including fertility outcomes in pediatric patients treated during infancy, is an active area of investigation, as studies to date have relied on short- to medium-term surrogate endpoints11.

§06History

Gonadorelin's development follows directly from the isolation and structural elucidation of hypothalamic gonadotropin-releasing hormone (GnRH), a landmark achievement for which Andrew Schally and Roger Guillemin were awarded the Nobel Prize in Physiology or Medicine in 1977. GnRH was first isolated from porcine and ovine hypothalami in the early 1970s and identified as the decapeptide regulator of pituitary gonadotropin secretion. Synthetic gonadorelin, chemically identical to native GnRH, was among the earliest research tools developed following this discovery and was rapidly advanced into clinical evaluation.

Gonadorelin received regulatory approval in the United States under the brand name Factrel (Wyeth) for diagnostic assessment of pituitary gonadotropin reserve and was used extensively in human clinical research through the 1980s and 1990s as a provocative testing agent17. Concurrently, it was developed for veterinary reproductive management, where it became a foundational component of synchronization protocols in dairy and beef cattle — a role that has expanded substantially as Ovsynch and related timed AI protocols were developed and validated from the late 1990s onward14,15.

In pediatric medicine, gonadorelin-based stimulation testing became a reference standard for diagnosing central precocious puberty, with subsequent research refining diagnostic thresholds and identifying the influence of covariates such as BMI on test interpretation16,20. Its application in cryptorchidism management — both for diagnosis and as neoadjuvant hormonal therapy — has been an area of clinical investigation for several decades, with long-term outcomes studies continuing into the 2020s1,11. In veterinary reproductive science, optimization of dose and protocol timing in synchronization programs remains an active and productive area of research2,3,7,8,10,19.

§07References